Green Cross pubish series of CB1 antagonists

Green Cross have published a series of biarylpyrazolyl oxadiazole based compounds as CB1 antagonists

Jenrin’s CB1 antagonists show efficacy with less adverse effects

Data presented at the Annual Scientific Meeting of the Obesity Society show Jenrin’s CB1 antagonist are capable of having a metabolic effect while reducing risks of psychiatric side effects.

J&J publish series of CCR2 antagonists

J&J have published a series of 7-Azaindole Piperidine CCR2 Antagonists

ChemoCentryx initiate Phase I trial of CCR9 antagonist CCX025

ChemoCentryx have initiated a Phase I clinical trial of CCX025, a CCR9 antagonist

FDA approves AstraZeneca’s Seroquel XR for the Treatment of Bipolar Depression and Bipolar Mania

The US FDA has approved AstraZeneca’s Seroquel XR for the Treatment of Bipolar Depression and Bipolar Mania in the US

Evotec initiate Phase I trial with P2X7 Antagonist

Evotec have initiated a Phase I clinical study of its proprietary, small molecule P2X7 receptor antagonist

Progenics completes enrollment in Phase II studies of CCR5 antagonist PRO-140

Progenics Pharmaceuticals have announced the completion of enrollment in two, phase 2 clinical studies of CCR5 antagonist PRO 140 in develompent for the treatment of human immunodeficiency virus (HIV)

Aeterna Zentaris complete recruitment for 2nd Cetrorelix BPH trial

Æterna Zentaris have completed patient recruitment its second Phase III efficacy trial of cetrorelic in benign prostatic hyperplasia (BPH)

ProStrakan receive FDA approval for Sancuso

ProStrakan Group has received FDA approval for Sancuso, it’s transdermal granisetron patch for the prevention of chemotherapy-induced nausea and vomiting (CINV).

Forest/Gedeon Richters Cariprazine effective in Acute Mania Associated with Bipolar I Disorder

Forest Laboratories  and Gedeon Richter have announced results from a phase II clinical trial of cariprazine (RGH-188) in patients with acute mania associated with bipolar I disorder. The data showed that patients with acute manic episodes treated with cariprazine experienced significant symptom improvement compared to placebo patients.